Fan Zhong Guo, Gao Xiao Fei, Li Xiao Bo, Shao Ming Xue, Gao Ya Li, Chen Shao Liang, Tian Nai Liang
Department of Cardiology, Nanjing First Hospital Nanjing Medical University; Nanjing-People's Republic of China.
Anatol J Cardiol. 2017 Apr;17(4):258-268. doi: 10.14744/AnatolJCardiol.2016.7461. Epub 2017 Mar 22.
The effects of intravascular ultrasound (IVUS)-guided drug-eluting stent (DES) implantation in patients with complex coronary artery lesions remains to be controversial. This study sought to evaluate the outcomes of IVUS guidance in these patients.
The EMBASE, Medline, and other internet sources were searched for relevant articles. The primary endpoint was major adverse cardiac events (MACE), including all-cause mortality, myocardial infarction (MI), and target-vessel revascularization (TVR). The incidence of definite/probable stent thrombosis (ST) was analyzed as the safety endpoint.
Fifteen clinical trials involving 8.084 patients were analyzed. MACE risk was significantly decreased following IVUS-guided DES implantation compared with coronary angiography (CAG) guidance (odds ratio [OR] 0.63, 95% confidence intervals [CI]: 0.53-0.73, p<0.001), which might mainly result from the lower all-cause mortality risk (OR 0.52, 95% CI: 0.40-0.67, p<0.001), MI (OR 0.70, 95% CI: 0.56-0.86, p=0.001), and TVR (OR 0.53, 95% CI: 0.40-0.70, p<0.001). The subgroup analyses indicated better outcomes of IVUS guidance in DES implantation for these patients with left main disease or bifurcation lesions.
IVUS guidance in DES implantation is associated with a significant reduction in MACE risk in patients with complex lesions, particularly those with left main disease or bifurcation lesions. More large and powerful randomized trials are still warranted to guide stenting decision making.
血管内超声(IVUS)引导下药物洗脱支架(DES)植入术在复杂冠状动脉病变患者中的疗效仍存在争议。本研究旨在评估IVUS引导在这些患者中的治疗效果。
检索EMBASE、Medline及其他网络资源以查找相关文章。主要终点为主要不良心脏事件(MACE),包括全因死亡率、心肌梗死(MI)和靶血管血运重建(TVR)。将明确/可能的支架血栓形成(ST)发生率作为安全性终点进行分析。
分析了15项涉及8084例患者的临床试验。与冠状动脉造影(CAG)引导相比,IVUS引导下DES植入术后MACE风险显著降低(优势比[OR]0.63,95%置信区间[CI]:0.53 - 0.73,p<0.001),这可能主要源于全因死亡率风险较低(OR 0.52,95% CI:0.40 - 0.67,p<0.001)、MI(OR 0.70,95% CI:0.56 - 0.86,p = 0.001)和TVR(OR 0.53,95% CI:0.40 - 0.70,p<0.001)。亚组分析表明,对于左主干病变或分叉病变患者,IVUS引导下DES植入术的效果更佳。
IVUS引导下DES植入术可显著降低复杂病变患者的MACE风险,尤其是左主干病变或分叉病变患者。仍需要更多大型、有力的随机试验来指导支架置入决策。